

## **INTRA-ARTICULAR ADMINISTRATION OF MD-HIP IN 7 PATIENTS AFFECTED BY HIP OSTEOARTHRITIS UNRESPONSIVE TO VISCOSUPPLEMENTATION. SIX-MONTH MULTICENTER TRIAL**

**Authors:** Migliore A., Massafra U., Bizzi E., Vacca F., Tormenta S.

– Clinical trial presented at the International Symposium Intra Articular Treatment; Rome (October 2011).

**Experimental sites:** UOS (Simple Operating Unit) of Rheumatology – San Pietro Fatebenefratelli Hospital, Rome.

**Pathologies considered:** osteoarthritis X-Ray I-III stage according to Kellgren-Lawrence affecting the hip joint unresponsive to viscosupplementation with hyaluronic acid (6 patients) or hylan (1 patient) (2 ultrasound guided injections at least).

**Outcomes:**

1)assessment of efficacy using VAS scale and Lequesne algofunctional Index;  
2)NSAIDs consumption before treatment and during follow-up. 3)safety profile of MD-Hip.

**Patients enrolled:** 7

**Treatment: MD-Hip** (2 ampoules = 4 ml), 1 ultrasound guided intra-articular injection.

**Results**

1)VAS of osteoarthritis pain = from 6.15 (before treatment) to 4.23 (after 3 months), to 4.23 (after 6 months).

2)Lequesne Index = from 1.94 (before treatment) to 5.9 (after 3 months), to 5.83 (after 6 months).

3)NSAIDs consumption = from 7.57 (before treatment) to 4.25 (after 3 months), to 5.78 (after 6 months).

– **Author's conclusions:**

1)MD-Hip showed to be effective (all the average values of the results at 3 and at 6 months after the last treatment have been statistically significant) and safe in patients affected by hip osteoarthritis unresponsive to viscosupplementation.

2)The data suggest that the results can be evident from the very first injection and are stable for 6 months.

3)The preliminary data offer new research opportunities in the field of intra-articular therapy.